Compare Novavax Inc (NVAX) vs Boston Beer Company Inc (SAM) Price & Performance

Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.

The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.

Boston Beer Company (SAM) trades at $168.16, down 1.3% with a neutral technical outlook. The stock shows mixed fundamentals with a P/E of 22.66 and P/S of 0.92, but negative net income margin of -3.64% and ROE of -8.61%. Recent earnings missed expectations in Q1 and Q2 2026, though Q4 2025 beat estimates. The company maintains positive operating cash flow of $270M in 2025 while expanding brand innovation with new product launches and marketing initiatives.

SAM faces headwinds from volume declines and cost pressures, but brand investments and new product categories offer growth potential. Analyst consensus is cautious with 72% hold ratings, though the $204.44 price target suggests 22% upside. Key risks include competitive pressures and shifting consumer preferences in the alcoholic beverage market.